Want to see RADX full AI Analyst Report?
Total Valuation
Radiopharm Theranostics Limited Sponsored ADR has a market cap or net worth of $31.08M. The enterprise value is $37.43.
Market Cap$31.08M
Enterprise Value$37.43
Share Statistics
Radiopharm Theranostics Limited Sponsored ADR has 14,458,498 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,458,498
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Radiopharm Theranostics Limited Sponsored ADR’s return on equity (ROE) is -2.18 and return on invested capital (ROIC) is -161.91%.
Return on Equity (ROE)-2.18
Return on Assets (ROA)-0.90
Return on Invested Capital (ROIC)-161.91%
Return on Capital Employed (ROCE)-1.62
Revenue Per Employee193.39K
Profits Per Employee-3.85M
Employee Count14
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Radiopharm Theranostics Limited Sponsored ADR is ―. Radiopharm Theranostics Limited Sponsored ADR’s PEG ratio is 0.10.
PE Ratio―
PS Ratio26.42
PB Ratio2.90
Price to Fair Value2.90
Price to FCF0.00
Price to Operating Cash Flow-0.60
PEG Ratio0.10
Income Statement
In the last 12 months, Radiopharm Theranostics Limited Sponsored ADR had revenue of 2.71M and earned -53.94M in profits. Earnings per share was -4.56.
Revenue2.71M
Gross Profit-2.10M
Operating Income-66.84M
Pretax Income-55.65M
Net Income-53.94M
EBITDA-66.84M
Earnings Per Share (EPS)-4.56
Cash Flow
In the last 12 months, operating cash flow was -54.34M and capital expenditures 32.08M, giving a free cash flow of -22.26M billion.
Operating Cash Flow-54.34M
Free Cash Flow-22.26M
Free Cash Flow per Share-1.54
Dividends & Yields
Radiopharm Theranostics Limited Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.99
52-Week Price Change-60.73%
50-Day Moving Average3.38
200-Day Moving Average4.41
Relative Strength Index (RSI)27.49
Average Volume (3m)127.34K
Important Dates
Radiopharm Theranostics Limited Sponsored ADR upcoming earnings date is Sep 24, 2026, TBA (Not Confirmed).
Last Earnings DateFeb 27, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
Radiopharm Theranostics Limited Sponsored ADR as a current ratio of 1.16, with Debt / Equity ratio of 0.00%
Current Ratio1.16
Quick Ratio1.16
Debt to Market Cap0.00
Net Debt to EBITDA0.06
Interest Coverage Ratio-607.93
Taxes
In the past 12 months, Radiopharm Theranostics Limited Sponsored ADR has paid -53.25K in taxes.
Income Tax-53.25K
Effective Tax Rate<0.01
Enterprise Valuation
Radiopharm Theranostics Limited Sponsored ADR EV to EBITDA ratio is -1.01, with an EV/FCF ratio of 0.00.
EV to Sales24.89
EV to EBITDA-1.01
EV to Free Cash Flow0.00
EV to Operating Cash Flow-1.31
Balance Sheet
Radiopharm Theranostics Limited Sponsored ADR has $4.14M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.14M billion.
Cash & Marketable Securities$4.14M
Total Debt$0.00
Net Cash$4.14M
Net Cash Per Share$0.29
Tangible Book Value Per Share$1.89
Margins
Gross margin is -39.41%, with operating margin of -2468.62%, and net profit margin of -1992.46%.
Gross Margin-39.41%
Operating Margin-2468.62%
Pretax Margin-2055.58%
Net Profit Margin-1992.46%
EBITDA Margin-2468.62%
EBIT Margin-2468.62%
Analyst Forecast
The average price target for Radiopharm Theranostics Limited Sponsored ADR is $16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.00
Price Target Upside589.66% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-19.76%
EPS Growth Forecast8.58%